Aims 3,4-Methylenedioxymethamphetamine (MDMA, commonly called ecstasy) is a synthetic compound increasingly popular as a recreational drug. Little is known about its pharmacology, including its metabolism and pharmacokinetics, in humans in controlled settings. A clinical trial was designed for the evaluation of MDMA pharmacological effects and pharmacokinetics in healthy volunteers. Methods A total of 14 subjects were included. In the pilot phase six received MDMA at 50 (n=2), 100 (n=2), and 150 mg (n=2). In the second phase eight received MDMA at both 75 and 125 mg (n=8). Subjects were phenotyped for CYP2D6 activity and were classified as extensive metabolizers for substrates, such as MDMA, whose hepatic metabolism is regulated by this enzyme. Plasma and urine samples were collected throughout the study for the evaluation of MDMA pharmacokinetics. Body fluids were analysed for the determination of MDMA and its main metabolites 3,4-methylenedioxyamphetamine (MDA), 4-hydroxy-3-methoxy-methamphetamine (HMMA) and 4-hydroxy-3-methoxy-amphetamine (HMA). Results As the dose of MDMA administered was increased, volunteers showed rises in MDMA concentrations that did not follow the same proportionality which could be indicative of nonlinearity. In the full range of doses tested the constant recovery of HMMA in the urine combined with the increasing MDMA recovery seems to point towards a saturation or an inhibition of MDMA metabolism (the demethylenation step). These observations are further supported by the fact that urinary clearance was rather constant while nonrenal clearance was dose dependent. Conclusions It has previously been postulated that individuals genetically deficient for the hepatic enzyme CYP2D6 (about 10% of the Caucasian people) were at risk of developing acute toxicity at moderate doses of MDMA because the drug would accumulate in the body instead of being metabolized and inactivated. The lack of linearity of MDMA pharmacokinetics (in a window of doses compatible with its recreational use) is a more general phenomenon as it concerns the whole population independent of their CYP2D6 genotype. It implies that relatively small increases in the dose of MDMA ingested are translated to disproportionate rises in MDMA plasma concentrations and hence subjects are more prone to develop acute toxicity.
Introduction reports have drawn attention to toxicity and deaths associated with MDMA use [2] . Neurodegenerative 3,4-Methylenedioxymethamphetamine (MDMA, commonly called ecstasy) is a synthetic compound that has effects on the central serotonergic system observed in animal models after MDMA exposure have been postubecome increasingly popular as a recreational drug amongst young people due to its entactogen (euphoria, lated as clinically relevant long-term forms of toxicity [3] [4] [5] . However, little is known about MDMA pharma- volunteers given low doses of MDMA (as compared with
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those normally ingested for recreational purposes), and three pharmacokinetic studies in a controlled setting that pharmacokinetics of MDMA. This has been further investigated in the present study. included four subjects have been published to date [6] [7] [8] [9] .
The metabolism of MDMA involves N-demethylation to 3,4-methylenedioxyamphetamine (MDA) (Figure 1 ). Methods The parent compound and MDA are further O-demethylenated to 3,4-dihydroxymethamphetamine Patients and study design (HHMA) and 3,4-dihydroxyamphetamine (HHA), respectively. Both HHMA and HHA are subsequently
The recreational use of MDMA on at least five occasions was required in subjects willing to participate in the O-methylated by catechol-O-methyltransferase (COMT) mainly to 4-hydroxy-3-methoxy-methamphetamine study. Male subjects were recruited by 'word of mouth' and eligible subjects were interviewed to exclude con-(HMMA) and 4-hydroxy-3-methoxy-amphetamine (HMA). These four metabolites, particularly HMMA and comitant underlying conditions. The presence of a major psychiatric disorder, assessed by means of the structured HMA, are known to be excreted in the urine as conjugated glucuronide or sulphate metabolites but data clinical interview for DSM-IV, was an exclusion criterion. Each subject underwent a physical examination, routine on quantitative recovery of the metabolites and the potential relationship with the administered dose are blood and urine laboratory testing and 12-lead electrocardiogram (ECG). A total of 14 volunteers were included, scarce [10] . CYP2D6 as for other oxidative metabolic reactions in the phenylalkylamines series, regulates the six in the pilot phase and eight in the final study. methamphetamine consumption. None had a history Analytical methods of abuse or drug dependence according to DSM-IV criteria (except for nicotine dependence), nor any Urine and plasma samples were analysed following a previously reported method based on solid-liquid extracmedical or psychiatric adverse reaction after MDMA consumption. tion and gas chromatography separation with nitrogen specific detection. MDMA, MDA, HMMA and HMA, All volunteers gave their written informed consent and were economically compensated for inconveniences were measured in plasma and urine samples either directly or after hydrolysis of glucuronide conjugates [15] . caused by their participation in the study. The present study was performed in accordance with the Declaration of Helsinki and after completing the following steps: (1) Data analysis peer review and approval of the clinical trial protocol by the institutional ethical committee (CEIC-IMAS); (2) Area under the plasma MDMA and metabolites concentration vs time curve (AUC(0,24)) was determined by peer review, authorization, and grant provision by public authorities for funding medical research in Spain (Fondo the linear trapezoidal rule. AUC were extrapolated to infinity (AUC(0,2)) by adding the last quantifiable de Investigaciones Sanitarias, FIS); and (3) peer review and authorization by the General Directorate of Pharmacy concentration divided by the elimination constant (l z ). Calculations were performed using PKCALC software and Health Products (DGFPS no. 95/297) of the Spanish Ministry of Health that procured also the MDMA [16] . (racemate) to be administered in the trial.
In a preliminary phase six healthy volunteers received Results 50, 100 and 150 mg of MDMA (two subjects for each dose) to determine the subsequent doses of MDMA to An initial assessment of MDMA and MDA concentrations in plasma samples of the definitive study suggested a be used in the definitive trial. The main criteria for the selection of doses included tolerance to the dose given nonproportional dose-dependent kinetics of MDMA and its metabolite MDA (Table 1) . A paired Student's t-test and sensitivity to a battery of tests regarding subjective effects and psychomotor performance. It appeared that of normalized AUC(0,2) (AUC/dose) obtained for MDMA 75 and 125 mg (n=8) showed statistically 50 mg was a quite low dose and that volunteers given 150 mg experienced several side-effects (cardiovascular, significant differences ( P<0.03). When combining these results with those obtained in the pilot studies, it was subjective effects) that prevented the use of this dose, so that 75 and 125 mg were the doses finally selected. In observed that whilst the range of doses evaluated had a factor of 3 (50-150 mg), the area under the curve the second phase, eight subjects participated in a doubleblind, randomised, crossover and controlled clinical study.
(AUC(0,24 h)) for MDMA showed a variation higher than 10 times. A non parametric comparison (KruskalTreatment conditions (MDMA 75 mg, MDMA 125 mg, (±)-amphetamine 40 mg and placebo) were randomly Wallis) of normalized data to a 100 mg MDMA dose of AUC(0,2) of the five doses assayed (50 n=2, 75 n=8, assigned using a balanced 4×4 latin-square design. Subjects were phenotyped for CYP2D6 activity using 100 n=2, 125 n=8 and 150 n=2) showed marginally significant differences amongst doses ( P<0.1). A biodextrometorphan as a probe drug [14] and the dextrometorphan/dextrorphan urinary metabolic ratio allowed all equivalence test comparing normalized AUC(0,2) (AUC/dose) for 75 and 125 mg (same eight subjects for the subjects to be classified as extensive metabolizers. Psychomotor performance tasks, subjective effects and each dose level) showed that the 90% confidence interval of the AUC within subjects ratio was −0.3-89.3%. As physiological variables (heart rate, blood pressure, oral temperature, pupillary diameter and ECG continuous standard bioequivalence tolerance intervals are set-up at ±20%, one can consider that the 125 mg MDMA dose monitoring) were measured.
An indwelling catheter was inserted in a peripheral was not bioequivalent showing a higher bioavailability. MDMA plasma clearance has been evaluated and divided vein and a 0.9% sodium chloride solution was infused at a rate of 20 ml h −1 . Blood was collected at baseline and into the renal and the nonrenal components of this pharmacokinetic parameter (see Table 1 ). It is apparent at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 h after MDMA administration. Urine samples were collected in that while urinary clearance was rather constant (an anova analysis for all doses tested was non significant), two periods (0-8 h and 8-24 h) for the preliminary phase and at three different periods (0-4 h, 4-8 h and 8-24 h) nonrenal clearance was dose dependent (anova analysis, P <0.03). These observations are of particular interest for in the second phase (doses of 75 and 125 mg). Urine was stored at −20°C until analysis. Blank urine samples were those subjects (the same eight subjects) that received both doses of 75 and 125 mg MDMA. Non-renal clearance is collected before drug administration to verify the absence of MDMA metabolites.
reduced by one-half for the 125 mg dose, strongly suggesting an impairment in the MDMA hepatic creatinine excretion rate were monitored in each urine collection period in order to exclude any bias induced clearance.
Urine samples for the 14 participating subjects were by changes in the normal renal excretion of these compounds. No significant changes were observed along also analysed for MDMA, MDA, HHMA and HMA. Urinary recoveries are shown in Table 2 . Some other the study. Urinary pH (always lower than 6.8) varied in less than 0.3 units and maximal differences in total minor MDMA metabolites already described were detected, but were not relevant quantitatively. MDA and creatinine clearance were always lower than 0.25 l h −1 .
Plasma samples from five volunteers, one for each dose HMA appeared to be very minor metabolites of MDMA. Independent of the dose administered, about 50% of the level, where re-analysed specifically for HMMA levels after enzymatic hydrolysis with -glucuronidase, as HMMA dose was recovered in 24 h. However, it was noted that while the HMMA (mainly excreted as conjugated with was absent in plasma in the nonconjugated fraction. Results are presented in Figures 2 and 3 . Whilst HMMA glucuronic acid) total recovery was almost constant (around 100 mmol) for the whole range of doses studied was the major product in plasma after the administration of 50, 75 and 100 mg, the situation was the opposite the recovery of MDMA increased in a nonproportional dose-response pattern. Although there was a factor of 3 when higher doses were given, with MDMA being predominant. This observation was based on AUCs and in the range of doses administered, recovery of MDMA was affected by a factor of nearly 20. Urinary pH and C max at the five doses tested. A cardiovascular variable, 
Discussion
The main finding of the present study is that as the MDMA dose is increased, the rise in MDMA concentrations does not follow the same proportionality, which could be indicative of nonlinearity. MDMA pharmacokinetic studies are scarce in the literature with data from only three volunteers (one from the study of Verebey and associates [7] and two from the study of Helmlin and coworkers studies with cell cultures expressing human CYP2D6 suggested that the demethylenation of MDMA to 3,4-dihydroxymethamphetamine (HHMA) was regulated by this enzyme [11, 17] . Nevertheless, HHMA is nearly such as diastolic blood pressure (DBP), supposed to be sensitive to MDMA plasma concentrations, was plotted undetectable in biological fluids as it is quickly methylated to HMMA most probably by the COMT enzyme. In against MDMA C max for each dose evaluated. DBP showed a similar behaviour to the plasma concentrations vitro data also suggest that MDMA, in addition to being a substrate, acts as an inhibitor of CYP2D6 activity. of MDMA (Figure 3) , with clear nonlinearity at the highest dose level. Taking into account the cardiovascular
Mechanisms involved in such inhibitory activity most probably include not only a competitive interaction effects experienced by the volunteers at the dose of 150 mg, it was considered not ethically feasible to between MDMA and CYP2D6 probe substrates but also the formation of a metabolic complex with CYP2D6 administer higher doses.
